{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:35:13Z","timestamp":1788543313039,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6099-x","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T12:04:29Z","timestamp":1567685069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-7418","authenticated-orcid":false,"given":"Monika K.","family":"Krzyzanowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim A.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Powis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Earle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Enright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen E.","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Grunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"6099_CR1","unstructured":"Cancer Quality Council of Ontario. Cancer System Quality Index (CSQI). 2017. \n                    http:\/\/www.csqi.on.ca\/\n                    \n                  . Accessed on 23 Feb 2018."},{"issue":"2","key":"6099_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JOP.2014.001073","volume":"11","author":"K Enright","year":"2015","unstructured":"Enright K, Grunfeld E, Yun L, Moineddin R, Ghannam M, Dent S, et al. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. J Oncol Pract. 2015;11(2):126\u201332.","journal-title":"J Oncol Pract"},{"issue":"4","key":"6099_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2141.2012.09177.x","volume":"158","author":"L Lee","year":"2012","unstructured":"Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol. 2012;158(4):481\u20138.","journal-title":"Br J Haematol"},{"issue":"19","key":"6099_CR4","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2013.49.3676","volume":"32","author":"CH Barcenas","year":"2014","unstructured":"Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol. 2014;32(19):2010\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6099_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaoncol.2015.3440","volume":"1","author":"RM Prince","year":"2015","unstructured":"Prince RM, Atenafu EG, Krzyzanowska MK. Hospitalizations during systemic therapy for metastatic lung cancer: a systematic review of real world vs clinical trial outcomes. JAMA Oncol. 2015;1(9):1333\u20139.","journal-title":"JAMA Oncol"},{"issue":"1","key":"6099_CR6","doi-asserted-by":"publisher","first-page":"e12909","DOI":"10.1111\/ecc.12909","volume":"28","author":"Rebecca M. Prince","year":"2018","unstructured":"Prince RM, Powis M, Zer A, Atenafu EG, Krzyzanowska MK. Hospitalizations and emergency department visits in cancer patients receiving chemotherapy: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2018:e12909.","journal-title":"European Journal of Cancer Care"},{"issue":"5","key":"6099_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ejon.2008.07.005","volume":"12","author":"N Kearney","year":"2008","unstructured":"Kearney N, Miller M, Maguire R, Dolan S, MacDonald R, McLeod J, et al. WISECARE+: results of a European study of a nursing intervention for the management of chemotherapy-related symptoms. Eur J Oncol Nurs. 2008;12(5):443\u20138.","journal-title":"Eur J Oncol Nurs"},{"issue":"4","key":"6099_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00520-008-0515-0","volume":"17","author":"N Kearney","year":"2008","unstructured":"Kearney N, McCann L, Norrie J, Taylor L, Gray P, McGee-Lennon M, et al. Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Support Care Cancer. 2008;17(4):437\u201344.","journal-title":"Support Care Cancer"},{"issue":"3","key":"6099_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1046\/j.1523-5394.2002.103006.x","volume":"10","author":"KH Mooney","year":"2002","unstructured":"Mooney KH, Beck SL, Friedman RH, Farzanfar R. Telephone-linked care for cancer symptom monitoring: a pilot study. Cancer Pract. 2002;10(3):147\u201354.","journal-title":"Cancer Pract"},{"issue":"9","key":"6099_CR10","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00520-014-2216-1","volume":"22","author":"KH Mooney","year":"2014","unstructured":"Mooney KH, Beck SL, Friedman RH, Farzanfar R, Wong B. Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: a randomized controlled clinical trial. Support Care Cancer. 2014;22(9):2343\u201350.","journal-title":"Support Care Cancer"},{"issue":"6","key":"6099_CR11","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1097\/NCC.0b013e3181b31114","volume":"32","author":"V Decker","year":"2009","unstructured":"Decker V, Spoelstra S, Miezio E, You M, Given B, Given CW. A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs. 2009;32(6):E20\u20139.","journal-title":"Cancer Nurs"},{"issue":"2","key":"6099_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine Cancer treatment. JAMA. 2017;318(2):197\u20138.","journal-title":"JAMA."},{"key":"6099_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40814-019-0404-y","volume":"5","author":"MK Krzyzanowska","year":"2019","unstructured":"Krzyzanowska MK, McKay C, Han H, Eberg M, Gandhi S, Laferriere NB, et al. Ambulatory toxicity management (AToM) pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer. Pilot Feasibility Stud. 2019;5:39.","journal-title":"Pilot Feasibility Stud"},{"issue":"2","key":"6099_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"6099_CR15","unstructured":"American Cancer Society [Internet]. Cancer Facts and Figures; 2017. [cited 27 February 2018]. Available from: \n                    https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2017\/cancer-facts-and-figures-2017.pdf\n                    \n                  ."},{"issue":"Suppl 1","key":"6099_CR16","first-page":"S1","volume":"4","author":"RW Carlson","year":"2006","unstructured":"Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, et al. NCCN task force report: adjuvant therapy for breast Cancer. J Natl Compr Cancer Netw. 2006;4(Suppl 1):S1\u201326.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"6099_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn HJ. 10th St. Gallen conference. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133\u201344.","journal-title":"Ann Oncol"},{"key":"6099_CR18","unstructured":"Cancer Care Ontario [Internet]. Toronto: Adjuvant Systemic Therapy for Node Negative Breast Cancer. Practice Guideline Report #1\u20138. [cited 27 February 2018]. Accessed from: \n                    https:\/\/www.cancercare.on.ca\/toolbox\/qualityguidelines\/diseasesite\/breast-ebs\/\n                    \n                  ."},{"issue":"9472","key":"6099_CR19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialist's Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet."},{"key":"6099_CR20","first-page":"246","volume":"95","author":"EA Clarke","year":"1991","unstructured":"Clarke EA, Marrett LD, Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ. 1991;95:246\u201357.","journal-title":"IARC Sci Publ"},{"issue":"3","key":"6099_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1191\/1740774504cn024oa","volume":"1","author":"LH Moulton","year":"2004","unstructured":"Moulton LH. Covariate-based constrained randomization of group-randomized trials. Clin Trials. 2004;1(3):297\u2013305.","journal-title":"Clin Trials"},{"issue":"4","key":"6099_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1740774508094747","volume":"5","author":"C Sismanidis","year":"2008","unstructured":"Sismanidis C, Moulton LH, Ayles H, Fielding K, Schaap A, Beyers N, et al. Restricted randomization of ZAMSTAR: a 2 x 2 factorial cluster randomized trial. Clin Trials. 2008;5(4):316\u201327.","journal-title":"Clin Trials"},{"issue":"26","key":"6099_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","volume":"344","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997\u20132008.","journal-title":"N Engl J Med"},{"issue":"8","key":"6099_CR24","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177\u201383.","journal-title":"J Clin Oncol"},{"issue":"36","key":"6099_CR25","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roch\u00e9","year":"2006","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol. 2006;24(36):5664\u201371.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6099_CR26","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E. Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014; 106(9): pii: dju244.","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"6099_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12955-016-0426-6","volume":"14","author":"AV Bennett","year":"2016","unstructured":"Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes. 2016;14:24.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"6099_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/082585979100700202","volume":"7","author":"E Bruera","year":"1991","unstructured":"Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991 Summer;7(2):6\u20139.","journal-title":"J Palliat Care"},{"issue":"3","key":"6099_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"6099_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/pon.1423","volume":"18","author":"AB Smith","year":"2009","unstructured":"Smith AB, Rush R, Wright P. Validation of an item bank for detecting and assessing psychological distress in cancer patients. Psychooncology. 2009;18:195\u20139.","journal-title":"Psychooncology."},{"issue":"3","key":"6099_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","volume":"46","author":"B Lowe","year":"2008","unstructured":"Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzog W, Herzberg PY. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care. 2008;46(3):266\u201374.","journal-title":"Med Care"},{"issue":"3","key":"6099_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of Cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974\u201386.","journal-title":"J Clin Oncol"},{"key":"6099_CR33","volume-title":"Development and Validation of the Picker Ambulatory Oncology Survey Instrument in Canada","author":"National Research Corporation, Ontario Hospital Association N.R.C","year":"2003","unstructured":"National Research Corporation, Ontario Hospital Association N.R.C. Development and Validation of the Picker Ambulatory Oncology Survey Instrument in Canada. Lincoln, NE: National Research Corporation; 2003."},{"issue":"5","key":"6099_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00520-012-1673-7","volume":"21","author":"A Husain","year":"2013","unstructured":"Husain A, Barbera L, Howell D, Moineddin R, Bezjak A, Sussman J. Advanced lung Cancer patients\u2019 experience with continuity of care and supportive care needs. Support Care Cancer. 2013 May;21(5):1351\u20138.","journal-title":"Support Care Cancer"},{"key":"6099_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejon.2012.10.012","volume":"17","author":"A Coolbrandt","year":"2013","unstructured":"Coolbrandt A, Van den Heede K, Jans E, Laenen A, Verslype C, Wildiers H, Milisen K. The Leuven questionnaire on patient knowledge of chemotherapy (L-PaKC): instrument development and psychometric evaluation. Eur J Oncol Nurs. 2013;17:465\u201373.","journal-title":"Eur J Oncol Nurs"},{"key":"6099_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1748-5908-2-40","volume":"2","author":"C Carroll","year":"2007","unstructured":"Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. Implement Sci. 2007;2:40.","journal-title":"Implement Sci"},{"issue":"8","key":"6099_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJMhle1312508","volume":"370","author":"SY Kim","year":"2014","unstructured":"Kim SY, Miller FG. Informed consent for pragmatic trials-the integrated consent model. N Engl J Med. 2014;370(8):769\u201372.","journal-title":"N Engl J Med"},{"key":"6099_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.","journal-title":"Implement Sci"},{"issue":"1","key":"6099_CR39","doi-asserted-by":"publisher","DOI":"10.2196\/10875","volume":"21","author":"L Warrington","year":"2019","unstructured":"Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, Velikova G. Electronic Systems for Patients to report and manage side effects of Cancer treatment: systematic review. J Med Internet Res. 2019;21(1):e10875.","journal-title":"J Med Internet Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6099-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6099-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6099-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:10:19Z","timestamp":1599174619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6099-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6099"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6099-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"4 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the Ontario Cancer Research Ethics Board, a centralized ethics board used by 18 of the participating cancer centres, the Sault Area Hospital Research Ethics Board, and the Rouge Valley Health System Research Ethics Board. For centres randomized to the intervention arm, the intervention will be introduced in the centre as a process change as per quality improvement principles hence individual written informed consent will be waived []. For control centres employing their local standard of care, as above, informed consent is also waived. Study-specific questionnaires and collection of OHIP number will only be completed by those patients voluntarily participating in the PRO sub-study, for which individual written informed consent is obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors CCE and EG hold appointments at the Ontario Institute for Cancer Research (OICR) Health Services Research Program. All other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"884"}}